Edwards Lifesciences (GB:0REN)
UK Market

Edwards Lifesciences Stock Analysis & Ratings

GB:0REN Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was SFr.0.00 and its highest was SFr.0.00 in the past 12 months.
    What is Edwards Lifesciences’s market cap?
    Currently, no data Available
    What is Edwards Lifesciences’s price target?
    The average price target for Edwards Lifesciences is SFr.130.56. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is SFr.144.15 ,the lowest forecast is SFr.114.32. The average price target represents N/A Increase from the current price of N/A.
      What do analysts say about Edwards Lifesciences?
      Edwards Lifesciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
        When is Edwards Lifesciences’s upcoming earnings report date?
        Edwards Lifesciences’s upcoming earnings report date is Jul 28, 2022 which is in 71 days.
          How were Edwards Lifesciences’s earnings last quarter?
          Edwards Lifesciences released its earnings results on Apr 26, 2022. The company reported SFr.0.601 earnings per share for the quarter, beating the consensus estimate of SFr.0.572 by SFr.0.029.
            Is Edwards Lifesciences overvalued?
            According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
              Does Edwards Lifesciences pay dividends?
              Edwards Lifesciences does not currently pay dividends.
              What is Edwards Lifesciences’s EPS estimate?
              Edwards Lifesciences’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Edwards Lifesciences have?
              Edwards Lifesciences has 621,750,000 shares outstanding.
                What happened to Edwards Lifesciences’s price movement after its last earnings report?
                Edwards Lifesciences reported an EPS of SFr.0.601 in its last earnings report, beating expectations of SFr.0.572. Following the earnings report the stock price went same N/A.
                  Which hedge fund is a major shareholder of Edwards Lifesciences?
                  Among the largest hedge funds holding Edwards Lifesciences’s share is Sands Capital Management LLC. It holds Edwards Lifesciences’s shares valued at 1B.


                    Edwards Lifesciences Stock Analysis

                    Smart Score
                    Price TargetStrong Buy
                    The Edwards Lifesciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                    Learn more about TipRanks Smart Score

                    Company Description

                    Edwards Lifesciences

                    Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.

                    Similar Stocks
                    Price & Change
                    Boston Scientific
                    ICU Medical

                    Popular Stocks

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis